Anthracycline cardiotoxicity in survivors of childhood cancer

Clinical course, protection, and treatment

Neha Bansal, Vivian I. Franco, Steven E Lipshultz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Childhood cancer survivors are now living longer as a result of advancements in cancer treatment, but not without consequences. Cardiovascular disease is the leading non-cancer-related cause of morbidity and mortality in long-term survivors of childhood cancer. Cardiotoxicity associated with cancer treatment in children can be pervasive, persistent, and progressive. Serum cardiac biomarker concentrations during therapy can predict late cardiotoxicity; although there is still a need for validated cardiac monitoring guidelines. The cardioprotective strategy of continuous infusion of doxorubicin, while showing short-term benefit in adults, provides no long-term cardioprotection or improvement in event-free survival over bolus-infusion in children with a diagnosis of acute lymphoblastic leukemia. However, dexrazoxane protects the heart from the cardiotoxic effects of anthracycline treatment and does not interfere with oncologic efficacy or increase the risk of second malignancies. The emerging field of cardio-oncology emphasizes the need for collaborations between cardiologists and oncologists to find a balance between oncologic efficacy and the risks of cardiotoxicity to maximize the quality of life and survival for long-term survivors of childhood cancer.

Original languageEnglish (US)
Pages (from-to)11-18
Number of pages8
JournalProgress in Pediatric Cardiology
Volume36
Issue number1-2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Anthracyclines
Survivors
Second Primary Neoplasms
Neoplasms
Dexrazoxane
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Doxorubicin
Disease-Free Survival
Cardiovascular Diseases
Biomarkers
Quality of Life
Guidelines
Morbidity
Survival
Mortality
Cardiotoxicity
Serum

Keywords

  • Anthracyclines
  • Cardiac late effects
  • Cardiotoxicity
  • Childhood cancer
  • Childhood cancer survivors
  • Dexrazoxane

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Anthracycline cardiotoxicity in survivors of childhood cancer : Clinical course, protection, and treatment. / Bansal, Neha; Franco, Vivian I.; Lipshultz, Steven E.

In: Progress in Pediatric Cardiology, Vol. 36, No. 1-2, 2014, p. 11-18.

Research output: Contribution to journalArticle

Bansal, Neha ; Franco, Vivian I. ; Lipshultz, Steven E. / Anthracycline cardiotoxicity in survivors of childhood cancer : Clinical course, protection, and treatment. In: Progress in Pediatric Cardiology. 2014 ; Vol. 36, No. 1-2. pp. 11-18.
@article{fca5c701ea1c4df6b240ebef98f89526,
title = "Anthracycline cardiotoxicity in survivors of childhood cancer: Clinical course, protection, and treatment",
abstract = "Childhood cancer survivors are now living longer as a result of advancements in cancer treatment, but not without consequences. Cardiovascular disease is the leading non-cancer-related cause of morbidity and mortality in long-term survivors of childhood cancer. Cardiotoxicity associated with cancer treatment in children can be pervasive, persistent, and progressive. Serum cardiac biomarker concentrations during therapy can predict late cardiotoxicity; although there is still a need for validated cardiac monitoring guidelines. The cardioprotective strategy of continuous infusion of doxorubicin, while showing short-term benefit in adults, provides no long-term cardioprotection or improvement in event-free survival over bolus-infusion in children with a diagnosis of acute lymphoblastic leukemia. However, dexrazoxane protects the heart from the cardiotoxic effects of anthracycline treatment and does not interfere with oncologic efficacy or increase the risk of second malignancies. The emerging field of cardio-oncology emphasizes the need for collaborations between cardiologists and oncologists to find a balance between oncologic efficacy and the risks of cardiotoxicity to maximize the quality of life and survival for long-term survivors of childhood cancer.",
keywords = "Anthracyclines, Cardiac late effects, Cardiotoxicity, Childhood cancer, Childhood cancer survivors, Dexrazoxane",
author = "Neha Bansal and Franco, {Vivian I.} and Lipshultz, {Steven E}",
year = "2014",
doi = "10.1016/j.ppedcard.2014.09.012",
language = "English (US)",
volume = "36",
pages = "11--18",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Anthracycline cardiotoxicity in survivors of childhood cancer

T2 - Clinical course, protection, and treatment

AU - Bansal, Neha

AU - Franco, Vivian I.

AU - Lipshultz, Steven E

PY - 2014

Y1 - 2014

N2 - Childhood cancer survivors are now living longer as a result of advancements in cancer treatment, but not without consequences. Cardiovascular disease is the leading non-cancer-related cause of morbidity and mortality in long-term survivors of childhood cancer. Cardiotoxicity associated with cancer treatment in children can be pervasive, persistent, and progressive. Serum cardiac biomarker concentrations during therapy can predict late cardiotoxicity; although there is still a need for validated cardiac monitoring guidelines. The cardioprotective strategy of continuous infusion of doxorubicin, while showing short-term benefit in adults, provides no long-term cardioprotection or improvement in event-free survival over bolus-infusion in children with a diagnosis of acute lymphoblastic leukemia. However, dexrazoxane protects the heart from the cardiotoxic effects of anthracycline treatment and does not interfere with oncologic efficacy or increase the risk of second malignancies. The emerging field of cardio-oncology emphasizes the need for collaborations between cardiologists and oncologists to find a balance between oncologic efficacy and the risks of cardiotoxicity to maximize the quality of life and survival for long-term survivors of childhood cancer.

AB - Childhood cancer survivors are now living longer as a result of advancements in cancer treatment, but not without consequences. Cardiovascular disease is the leading non-cancer-related cause of morbidity and mortality in long-term survivors of childhood cancer. Cardiotoxicity associated with cancer treatment in children can be pervasive, persistent, and progressive. Serum cardiac biomarker concentrations during therapy can predict late cardiotoxicity; although there is still a need for validated cardiac monitoring guidelines. The cardioprotective strategy of continuous infusion of doxorubicin, while showing short-term benefit in adults, provides no long-term cardioprotection or improvement in event-free survival over bolus-infusion in children with a diagnosis of acute lymphoblastic leukemia. However, dexrazoxane protects the heart from the cardiotoxic effects of anthracycline treatment and does not interfere with oncologic efficacy or increase the risk of second malignancies. The emerging field of cardio-oncology emphasizes the need for collaborations between cardiologists and oncologists to find a balance between oncologic efficacy and the risks of cardiotoxicity to maximize the quality of life and survival for long-term survivors of childhood cancer.

KW - Anthracyclines

KW - Cardiac late effects

KW - Cardiotoxicity

KW - Childhood cancer

KW - Childhood cancer survivors

KW - Dexrazoxane

UR - http://www.scopus.com/inward/record.url?scp=84925943320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925943320&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2014.09.012

DO - 10.1016/j.ppedcard.2014.09.012

M3 - Article

VL - 36

SP - 11

EP - 18

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1-2

ER -